264 related articles for article (PubMed ID: 37905657)
21. Association of immune checkpoint inhibitors with respiratory infections: A review.
Hamashima R; Uchino J; Morimoto Y; Iwasaku M; Kaneko Y; Yamada T; Takayama K
Cancer Treat Rev; 2020 Nov; 90():102109. PubMed ID: 33038863
[TBL] [Abstract][Full Text] [Related]
22. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy.
Wong SK; Nebhan CA; Johnson DB
Front Immunol; 2021; 12():786046. PubMed ID: 34868071
[TBL] [Abstract][Full Text] [Related]
23. Key considerations and common adverse events for HIV-positive patients with cancer treated with immune checkpoint inhibitors.
Yekedüz E; Utkan G; Ürün Y
Future Oncol; 2022 Feb; 18(4):413-416. PubMed ID: 35018793
[TBL] [Abstract][Full Text] [Related]
24. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
25. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
Oladejo M; Paulishak W; Wood L
Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
[TBL] [Abstract][Full Text] [Related]
26. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint blockade for organ-transplant recipients with cancer: A review.
Rünger A; Schadendorf D; Hauschild A; Gebhardt C
Eur J Cancer; 2022 Nov; 175():326-335. PubMed ID: 36191571
[TBL] [Abstract][Full Text] [Related]
28. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity.
Motofei IG
Expert Opin Drug Saf; 2022 May; 21(5):599-612. PubMed ID: 34937484
[TBL] [Abstract][Full Text] [Related]
29. Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies.
Lombardi A; Saydere A; Ungaro R; Bozzi G; Viero G; Bandera A; Gori A; Mondelli MU
Int J Infect Dis; 2022 Jul; 120():77-82. PubMed ID: 35429642
[TBL] [Abstract][Full Text] [Related]
30. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review).
Wang Y; Yang S; Wan L; Ling W; Chen H; Wang J
Int J Oncol; 2023 Jul; 63(1):. PubMed ID: 37326100
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society.
Kwon H; Roh E; Ahn CH; Kim HK; Ku CR; Jung KY; Lee JH; Kim EH; Suh S; Hong S; Ha J; Moon JS; Kim JH; Kim MK;
Endocrinol Metab (Seoul); 2022 Dec; 37(6):839-850. PubMed ID: 36604955
[TBL] [Abstract][Full Text] [Related]
32. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
33. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review.
Collins M; Soularue E; Marthey L; Carbonnel F
Clin Gastroenterol Hepatol; 2020 May; 18(6):1393-1403.e1. PubMed ID: 32007539
[TBL] [Abstract][Full Text] [Related]
34. The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature.
Fejza A; Carobolante G; Poletto E; Camicia L; Schinello G; Di Siena E; Ricci G; Mongiat M; Andreuzzi E
Front Immunol; 2023; 14():1270981. PubMed ID: 37854588
[TBL] [Abstract][Full Text] [Related]
35. Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials.
Fujiwara Y; Kuchiba A; Koyama T; Machida R; Shimomura A; Kitano S; Shimizu T; Yamamoto N
ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32276948
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and therapeutic approach to pulmonary infiltrates in cancer patients receiving immune checkpoint inhibitors.
Fernández-Ruiz M
Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):67-73. PubMed ID: 36285862
[TBL] [Abstract][Full Text] [Related]
37. Endocrine toxicities of immune checkpoint inhibitors.
Wright JJ; Powers AC; Johnson DB
Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
[TBL] [Abstract][Full Text] [Related]
38. Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections.
Lu M; Zhang L; Li Y; Wang H; Guo X; Zhou J; Duan L; Si X; Xu Y; Zhang L
Thorac Cancer; 2020 Mar; 11(3):805-809. PubMed ID: 31970940
[TBL] [Abstract][Full Text] [Related]
39. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy.
Ho AK; Ho AM; Cooksley T; Nguyen G; Erb J; Mizubuti GB
Anesth Analg; 2021 Feb; 132(2):374-383. PubMed ID: 33009134
[TBL] [Abstract][Full Text] [Related]
40. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
